Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TANZEUM is a fusion protein injectable biologic approved by GSK in April 2014 as a Biologics License Application (BLA). The drug's specific mechanism of action and approved indications are not detailed in available data, but its fusion protein modality suggests a dual-target or receptor-ligand mechanism. It is currently in peak commercial lifecycle stage.
Peak
Drug is at peak commercial stage with moderate competitive pressure (30% intensity), suggesting stable sales infrastructure and mature team organization rather than high-growth hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TANZEUM at peak lifecycle offers stable, execution-focused career opportunities in brand management, sales, and market access rather than high-growth or innovation-heavy roles. Working on a mature biologic provides deep expertise in reimbursement, payer negotiations, and competitive positioning in a moderately pressured market.
Brand ManagerMedical Science Liaison
Worked on TANZEUM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.